BI-685509 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Liver Cirrhosis. According to GlobalData, Phase II drugs for Liver Cirrhosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-685509 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-685509 is under development for the treatment of clinically significant portal hypertension, cirrhosis, diabetic nephropathy, adults with early progressive diffuse cutaneous systemic sclerosis and chronic kidney disease. It is administered orally as a tablet. It acts by targeting soluble guanylate cyclase (sGC).
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
For a complete picture of BI-685509’s drug-specific PTSR and LoA scores, buy the report here.